ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma
Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, ...
ClarIDHy: Targeted therapy ivosidenib for advanced cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )
30 Sep 2019
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced ...
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced castration resistant prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
30 Sep 2019
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
PARP inhibitor olaparib slows progression of advanced prostate cancer
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )
30 Sep 2019
Comment: PARP inhibitors for advanced prostate cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Comment: Immunotherapy plus chemotherapy in bladder cancer
Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain
Comment: Immunotherapy plus chemotherapy in bladder cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )
30 Sep 2019
Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma
Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, ...
Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )
30 Sep 2019
Atezolizumab added to chemotherapy prolongs progression free survival in bladder...
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
Comment: Targeted therapy ivosidenib in cholangiocarcinoma
Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK
Comment: Targeted therapy ivosidenib in cholangiocarcinoma ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )
30 Sep 2019
BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mu...
Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Sp...
BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer ( Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )
30 Sep 2019
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early tripl...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019